Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 2200 of 2529 entries
View as:

Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants.

Phase: N/A Priority: Normal
NCT ID: NCT01961609 Org: User:
Start: 10/09/13 End: 07/12/16 Due: 07/12/17

Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D (RHYTHM)

Phase: N/A Priority: Normal
NCT ID: NCT04491136 Org: User:
Start: 11/11/20 End: 06/08/23 Due: 06/08/24

Efficacy of Telbivudine in Blacks/African Americans and Hispanics/Latinos With Compensated Chronic Hepatitis B During 52 Weeks

Phase: N/A Priority: Normal
NCT ID: NCT00862706 Org: User:
Start: 04/30/09 End: 04/30/11 Due: 04/30/12

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05132075 Org: User:
Start: 06/15/22 End: 03/30/26 Due: 03/30/27

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

Phase: N/A Priority: Normal
NCT ID: NCT06643481 Org: User:
Start: 10/17/24 End: 06/20/28 Due: 06/20/29

Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study

Phase: N/A Priority: Normal
NCT ID: NCT06958315 Org: User:
Start: 06/16/25 End: 12/31/26 Due: 12/31/27

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

Phase: N/A Priority: Normal
NCT ID: NCT01742299 Org: User:
Start: 03/26/13 End: 04/21/33 Due: 04/21/34

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

Phase: N/A Priority: Normal
NCT ID: NCT04266301 Org: User:
Start: 06/08/20 End: 10/02/24 Due: 10/02/25

Health-related Quality of Life, Symptom Severity, and Pain Among Patients With PIK3CA-related Overgrowth Spectrum: A Mixed-methods Observational Study

Phase: N/A Priority: Normal
NCT ID: NCT05294289 Org: User:
Start: 05/16/22 End: 06/28/24 Due: 06/28/25

Roll-over Study to Allow Continued Access to Ribociclib

Phase: N/A Priority: Normal
NCT ID: NCT05161195 Org: User:
Start: 07/07/22 End: 08/14/30 Due: 08/14/31

Asciminib RMP Study

Phase: N/A Priority: Normal
NCT ID: NCT05943522 Org: User:
Start: 07/19/23 End: 07/31/25 Due: 07/31/26

Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

Phase: N/A Priority: Normal
NCT ID: NCT04810611 Org: User:
Start: 06/18/21 End: 04/19/24 Due: 04/19/25

Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy

Phase: N/A Priority: Normal
NCT ID: NCT00248131 Org: User:
Start: 11/30/05 End: 07/31/06 Due: 07/31/07

Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma

Phase: N/A Priority: Normal
NCT ID: NCT03150160 Org: User:
Start: 09/21/17 End: 12/04/17 Due: 12/04/18

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Phase: N/A Priority: Normal
NCT ID: NCT05030428 Org: User:
Start: 11/23/21 End: 10/13/27 Due: 10/13/28

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

Phase: N/A Priority: Normal
NCT ID: NCT04948333 Org: User:
Start: 10/13/21 End: 02/03/26 Due: 02/03/27

Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Phase: N/A Priority: Normal
NCT ID: NCT04677595 Org: User:
Start: 05/17/21 End: 05/22/25 Due: 05/22/26

A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

Phase: N/A Priority: Normal
NCT ID: NCT05885555 Org: User:
Start: 08/16/23 End: 03/19/29 Due: 03/19/30

Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors

Phase: N/A Priority: Normal
NCT ID: NCT05853458 Org: User:
Start: 07/28/23 End: 01/27/27 Due: 01/27/28

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05827081 Org: User:
Start: 02/28/24 End: 09/20/30 Due: 09/20/31

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Phase: N/A Priority: Normal
NCT ID: NCT05445843 Org: User:
Start: 10/31/22 End: 11/30/27 Due: 11/30/28

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

Phase: N/A Priority: Normal
NCT ID: NCT01789281 Org: User:
Start: 05/14/13 End: 08/28/20 Due: 08/28/21

Pediatric Long-Term Follow-up and Rollover Study

Phase: N/A Priority: Normal
NCT ID: NCT03975829 Org: User:
Start: 11/04/19 End: 07/22/26 Due: 07/22/27

A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01621633 Org: User:
Start: 09/30/12 End: 01/31/13 Due: 01/31/14

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

Phase: N/A Priority: Normal
NCT ID: NCT03742349 Org: User:
Start: 01/31/19 End: 02/06/23 Due: 02/06/24